FindTrial
Sign In

Evaluation of Lofexidine for Treatment of Opiate Withdrawal - 10

Evaluation of Lofexidine for Treatment of Opiate Withdrawal

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00000345
Enrollment
0
Registered
1999-09-21
Start date
1996-04-30
Completion date
Unknown
Last updated
2017-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid-Related Disorders

Keywords

opioid dependence

Brief summary

The purpose of this study is to assess the safety of lofexidine in the treatment of opiate-dependent individuals.

Interventions

DRUGLofexidine

Sponsors

National Institute on Drug Abuse (NIDA)
Lead SponsorNIH

Study design

Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

M/F ages 21-50. Meet DSM-IV criteria for opiate dependence. Agree to conditions of the study and sign informed consent.

Exclusion criteria

Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical condtions that deem participation to be unsafe.

Design outcomes

Primary

MeasureTime frame
Opiate withdrawal—
Adverse effect measures—
Craving of opiates—
Liking of opiates—
Efficacy of lofexidine—
Euphoria—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026